61-75 of 92
ICI Combination Regimens for First-Line Treatment of Metastatic ESCC
MinuteCE®ICI Combination Regimens for First-Line Treatment of Metastatic ESCC
Harry Yoon, MD
Jaffer Ajani, MD
The Importance of PD-L1 Testing: Shaping the Future of Treatment in ESCC
MinuteCE®The Importance of PD-L1 Testing: Shaping the Future of Treatment in ESCC
Harry Yoon, MD
Tailoring First-Line Regimens: Patient-Centric Selection in Metastatic ESCC
MinuteCE®Tailoring First-Line Regimens: Patient-Centric Selection in Metastatic ESCC
Harry Yoon, MD
Jaffer Ajani, MD
Distinguishing Between Anti-PD-1 Agents in ESCC Combination Therapies
MinuteCE®Distinguishing Between Anti-PD-1 Agents in ESCC Combination Therapies
Jaffer Ajani, MD
The Impact of First-Line Treatment on Subsequent Treatment Options for Metastatic ESCC
MinuteCE®The Impact of First-Line Treatment on Subsequent Treatment Options for Metastatic ESCC
Harry Yoon, MD
Jaffer Ajani, MD
Harry Yoon, MD
Jaffer Ajani, MD
- advertisement
Chairperson’s Perspective: Treating At-Risk MASH: What Are You Waiting For?
CME/CEChairperson’s Perspective: Treating At-Risk MASH: What Are You Waiting For?
Mazen Noureddin, MD, MHSc
Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective
CME/CEAdvances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective
Naim Alkhouri, MD, FAASLD, DABOM
The Changing Paradigm of Treating MASLD/MASH: At the Crossroads of Hepato-Cardiometabolic Care – Chair’s Perspective
CME/CEThe Changing Paradigm of Treating MASLD/MASH: At the Crossroads of Hepato-Cardiometabolic Care – Chair’s Perspective
Naim Alkhouri, MD, FAASLD, DABOM
Advances in the Treatment and Management of MASH: More Options, More Decisions
CME/CE Broadcast ReplayAdvances in the Treatment and Management of MASH: More Options, More Decisions
Mary E. Rinella, MD, FAASLD
Naga Chalasani, MD, FAASLD
Mazen Noureddin, MD, MHSc
Practical Management of Variceal Bleeding and Hepatorenal Syndrome
CME/CEPractical Management of Variceal Bleeding and Hepatorenal Syndrome
Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Andrew Keaveny, MD
Don Rockey, MD
The Treatment Pipeline for Primary Biliary Cholangitis: Sorting Out the PPARs
MinuteCE®The Treatment Pipeline for Primary Biliary Cholangitis: Sorting Out the PPARs
Atoosa Rabiee, MD
Kris V. Kowdley, MD, AGAF, FAASLD, FACP, FACG
- advertisement
Your Patient's PBC Treatment: Long-Term Monitoring and Management
MinuteCE®Your Patient's PBC Treatment: Long-Term Monitoring and Management
Kris V. Kowdley, MD, AGAF, FAASLD, FACP, FACG
Marlyn Mayo, MD
Goals of Treatment for Primary Biliary Cholangitis: A Balancing Act
MinuteCE®Goals of Treatment for Primary Biliary Cholangitis: A Balancing Act
Kris V. Kowdley, MD, AGAF, FAASLD, FACP, FACG
Kris V. Kowdley, MD, AGAF, FAASLD, FACP, FACG
